{"altmetric_id":1886992,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["BehaviourPharma"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa60d3cf058f610006c00","doi":"10.1097\/01.fbp.0000435055.98980.de","first_seen_on":"2013-11-06T14:42:31+00:00","issns":["0955-8810"],"issue":"","journal":"Behavioural Pharmacology","last_mentioned_on":1383748937,"links":["http:\/\/journals.lww.com\/behaviouralpharm\/Citation\/2013\/10001\/G_12___Contribution_of_Mu_Opioid_Receptor.206.aspx"],"pdf_url":"http:\/\/pdfs.journals.lww.com\/behaviouralpharm\/2013\/10001\/G_12___Contribution_of_Mu_Opioid_Receptor.206.pdf","pubdate":"2013-10-01T00:00:00+00:00","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"startpage":"e59","subjects":["behavioralsciences","pharmacology"],"title":"G.12 - CONTRIBUTION OF MU OPIOID RECEPTOR EXPRESSED IN GABAERGIC FOREBRAIN NEURONS TO ADDICTION: A CONDITIONAL KNOCKOUT APPROACH","type":"article","volume":"24"},"altmetric_score":{"score":0.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.5},"context_for_score":{"all":{"total_number_of_other_articles":4505550,"mean":5.102354651723,"rank":3142934,"this_scored_higher_than_pct":22,"this_scored_higher_than":1018781,"rank_type":"exact","sample_size":4505550,"percentile":22},"similar_age_3m":{"total_number_of_other_articles":104236,"mean":7.739710039814,"rank":73177,"this_scored_higher_than_pct":22,"this_scored_higher_than":23136,"rank_type":"exact","sample_size":104236,"percentile":22},"this_journal":{"total_number_of_other_articles":570,"mean":2.0020351493849,"rank":417,"this_scored_higher_than_pct":15,"this_scored_higher_than":88,"rank_type":"exact","sample_size":570,"percentile":15},"similar_age_this_journal_3m":{"total_number_of_other_articles":42,"mean":1.2780487804878,"rank":27,"this_scored_higher_than_pct":7,"this_scored_higher_than":3,"rank_type":"exact","sample_size":42,"percentile":7}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/BehaviourPharma\/status\/398098014004207616","license":"public","citation_ids":[1886992],"posted_on":"2013-11-06T14:42:17+00:00","author":{"name":"Behavioural Pharma","url":"http:\/\/www.behaviouralpharm.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2579413827\/w4f03osopznbcrxnyvoz_normal.jpeg","description":"Publishing original research reports ranging from ethopharmacology to the pharmacology of operant behaviour","id_on_source":"BehaviourPharma","tweeter_id":"614452758","geo":{"lt":null,"ln":null},"followers":112},"tweet_id":"398098014004207616"}]}}